Skip to content

Drug interactions and duplicate prescriptions among ambulatory cancer patients.

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients; a prevalence study using new screening methods.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON22605
Enrollment
300
Registered
2010-03-09
Start date
2009-11-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug interaction, ambulatory cancer patients, OTC drugs.

Interventions

The patients are asked to complete a short questionnaire followed by an interview. The questionnaire contains questions about the demographic characteristics (available online as appendix). A list of

Sponsors

VU university medical center, Zaans Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with solid and hematologic malignancy currently using systemic anti-cancer drugs are asked to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Unable to fill out questionnaires; 2. The use of trial medication; 3. A lack of command of the Dutch language; 4. Younger than 18 years old.

Design outcomes

Primary

MeasureTime frame
The aim of the present study is to gain more insight into the prevalence of interactions and duplicate prescriptions among cancer patients being treated in the outpatient day care departments for oncology and hemato-oncology. This will be the first study into the prevalence of drug interactions with OTC-drugs in cancer patients.

Secondary

MeasureTime frame
Possible risk factors for the occurrence of these drug-related problems will also be studied.

Contacts

Public ContactJ.G. Hugtenburg

Clinical Pharmacology and Pharmacy VU University Medical Center PO Box 7057

jg.hugtenburg@vumc.nl00 31 20 4448090

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)